176 related articles for article (PubMed ID: 16408072)
21. Enantioselective synthesis of derivatives and structure-activity relationship study in the development of NA255 as a novel host-targeting anti-HCV agent.
Kawasaki K; Masubuchi M; Hayase T; Komiyama S; Watanabe F; Fukuda H; Murata T; Matsubara Y; Koyama K; Shindoh H; Sakamoto H; Okamato K; Ohta A; Katsume A; Aoki M; Aoki Y; Shimma N; Sudoh M; Tsukuda T
Bioorg Med Chem Lett; 2013 Jan; 23(1):336-9. PubMed ID: 23164713
[TBL] [Abstract][Full Text] [Related]
22. Subproteomic study of hepatitis C virus replicon reveals Ras-GTPase-activating protein binding protein 1 as potential HCV RC component.
Yi Z; Fang C; Pan T; Wang J; Yang P; Yuan Z
Biochem Biophys Res Commun; 2006 Nov; 350(1):174-8. PubMed ID: 16996479
[TBL] [Abstract][Full Text] [Related]
23. Cellular and molecular biology of HCV infection and hepatitis.
Tang H; Grisé H
Clin Sci (Lond); 2009 Jun; 117(2):49-65. PubMed ID: 19515018
[TBL] [Abstract][Full Text] [Related]
24. [HCV proteins suppress translation].
Kato J; Kato N; Shiratori Y; Omata M
Nihon Rinsho; 2001 Jul; 59(7):1254-8. PubMed ID: 11494533
[TBL] [Abstract][Full Text] [Related]
25. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
[TBL] [Abstract][Full Text] [Related]
26. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
[TBL] [Abstract][Full Text] [Related]
27. [Suppression of hepatitis C virus (HCV) replication with serine palmitoyltransferase inhibitor].
Hirata Y; Sudoh M; Kohara M
Yakugaku Zasshi; 2010 Feb; 130(2):157-61. PubMed ID: 20118637
[TBL] [Abstract][Full Text] [Related]
28. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon.
Qureshi SA
Med Res Rev; 2007 May; 27(3):353-73. PubMed ID: 16958135
[TBL] [Abstract][Full Text] [Related]
30. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
[TBL] [Abstract][Full Text] [Related]
31. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
[TBL] [Abstract][Full Text] [Related]
32. Visualization of the structures of the hepatitis C virus replication complex.
Chan SC; Lo SY; Liou JW; Lin MC; Syu CL; Lai MJ; Chen YC; Li HC
Biochem Biophys Res Commun; 2011 Jan; 404(1):574-8. PubMed ID: 21147066
[TBL] [Abstract][Full Text] [Related]
33. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
[TBL] [Abstract][Full Text] [Related]
34. Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis.
Hirata Y; Ikeda K; Sudoh M; Tokunaga Y; Suzuki A; Weng L; Ohta M; Tobita Y; Okano K; Ozeki K; Kawasaki K; Tsukuda T; Katsume A; Aoki Y; Umehara T; Sekiguchi S; Toyoda T; Shimotohno K; Soga T; Nishijima M; Taguchi R; Kohara M
PLoS Pathog; 2012; 8(8):e1002860. PubMed ID: 22916015
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of HCV replication by oxysterol-binding protein-related protein 4 (ORP4) through interaction with HCV NS5B and alteration of lipid droplet formation.
Park IW; Ndjomou J; Wen Y; Liu Z; Ridgway ND; Kao CC; He JJ
PLoS One; 2013; 8(9):e75648. PubMed ID: 24069433
[TBL] [Abstract][Full Text] [Related]
36. Annexin A2 is involved in the formation of hepatitis C virus replication complex on the lipid raft.
Saxena V; Lai CK; Chao TC; Jeng KS; Lai MM
J Virol; 2012 Apr; 86(8):4139-50. PubMed ID: 22301157
[TBL] [Abstract][Full Text] [Related]
37. Rescue of cell growth by sphingosine with disruption of lipid microdomain formation in Saccharomyces cerevisiae deficient in sphingolipid biosynthesis.
Tani M; Kihara A; Igarashi Y
Biochem J; 2006 Feb; 394(Pt 1):237-42. PubMed ID: 16225461
[TBL] [Abstract][Full Text] [Related]
38. HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis.
Loizides-Mangold U; Clément S; Alfonso-Garcia A; Branche E; Conzelmann S; Parisot C; Potma EO; Riezman H; Negro F
PLoS One; 2014; 9(12):e115309. PubMed ID: 25522003
[TBL] [Abstract][Full Text] [Related]
39. Modification of host lipid raft proteome upon hepatitis C virus replication.
Mannová P; Fang R; Wang H; Deng B; McIntosh MW; Hanash SM; Beretta L
Mol Cell Proteomics; 2006 Dec; 5(12):2319-25. PubMed ID: 16943187
[TBL] [Abstract][Full Text] [Related]
40. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus.
Rodgers MA; Villareal VA; Schaefer EA; Peng LF; Corey KE; Chung RT; Yang PL
J Am Chem Soc; 2012 Apr; 134(16):6896-9. PubMed ID: 22480142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
